drugset
drugset / Trial / NCT03929965

Anlotinib in Advanced Solid Tumors With FGFR Alteration

NCT03929965 ↗

Unknown 30 enrolled Shanghai Changzheng Hospital
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.

Timeline

Start
2019-07-01
Primary completion
2020-07-01
Completion
2023-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule — —

Indications

neoplasm